SecBot SecBot
8-K ·Filed May 12, 2026

ALKS

Alkermes plc.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001193125-26-218150
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The Phase 3 success removes clinical risk for LUMRYZ in IH, but the 2028 marketing restriction caps near-term revenue upside. Watch for sNDA filing progress and FDA acceptance in H2 2026; any update on the settlement agreement timeline could be a catalyst. The stock may gap up on the clinical data but the delayed commercial launch limits the magnitude.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$38.26
T+0 close · May 12, 2026 · via day close
Latest settled
+25.88%
T+60 · $48.16
Vs SPY
+21.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $38.26entry
  2. T+1 · 6mo ago +1.31%α +0.73% · $38.76
  3. T+5 · 6mo ago −2.79%α −2.87% · $37.19
  4. T+20 · 5mo ago +14.59%α +16.32% · $43.84
  5. T+60 · 3mo ago +25.88%α +21.76% · $48.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alkermes announced positive topline results from the REVITALYZ Phase 3 study of LUMRYZ in idiopathic hypersomnia (IH), meeting all primary and key secondary endpoints with high statistical significance (p<0.0001). The company plans to file an sNDA with the FDA by end of 2026, but a prior settlement agreement bars marketing LUMRYZ for IH before March 1, 2028, even if approved. This is a clear clinical win that expands LUMRYZ's addressable market into a rare disease affecting ~40,000 U.S. patients, though commercial upside is delayed by the marketing restriction.

Key Facts

  • LUMRYZ met the primary endpoint (ESS, p<0.0001) and all key secondary endpoints (PGI-C, IHSS, both p<0.0001) in the REVITALYZ Phase 3 study for idiopathic hypersomnia.
  • Safety profile consistent with known LUMRYZ data; no new safety signals observed.
  • Alkermes plans to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026.
  • A prior settlement and license agreement prohibits marketing LUMRYZ for IH before March 1, 2028, even if FDA approval is granted earlier.
  • Idiopathic hypersomnia affects an estimated 40,000 people in the U.S., representing a new, addressable rare disease market for LUMRYZ.

Financial Impact

No financial figures provided in the filing. LUMRYZ is already approved for narcolepsy; IH label expansion opens a new market of ~40,000 U.S. patients, but commercialization is barred until March 1, 2028.

revenue

Risk Factors

  • Marketing restriction until March 1, 2028 limits near-term revenue from IH even if FDA approves.
  • FDA may not accept or approve the sNDA; regulatory risk remains.
  • Competition from other IH treatments could emerge before 2028.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-218150
Document: alks-20260512.htm0001193125-26-218150
Document: 0001193125-26-218150-index-headers.html0001193125-26-218150
Document: 0001193125-26-218150-index.html0001193125-26-218150
Document: 0001193125-26-218150.txt0001193125-26-218150

US Market Status

Market Closed · Opens Wed (10h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026